Malpractice Concerns Affect Derm-Path Interpretive Behavior

This article originally appeared here.
Share this content:
Malpractice Concerns Affect Derm-Path Interpretive Behavior
Malpractice Concerns Affect Derm-Path Interpretive Behavior

MONDAY, Feb. 1, 2016 (HealthDay News) -- Many dermatopathologists believe that malpractice concerns may lead to additional testing in their evaluation of cutaneous melanocytic lesions, according to research published in the February issue of the Journal of the American Academy of Dermatology.

Patricia A. Carney, Ph.D., of the Oregon Health and Science University in Portland, and colleagues conducted a survey of dermatopathologists who interpret melanocytic skin lesions to assess how concerns about malpractice and experience with malpractice lawsuits influence their practice.

Two hundred seven (68.8 percent) of 301 dermatopathologists responded to the survey. The researchers found that 33 percent reported past experiences with malpractice. Factors significantly associated with being sued for malpractice included older age, lack of board certification or fellowship training in dermatopathology, and greater number of years spent interpreting melanocytic lesions. Despite the belief of most dermatopathologists that malpractice concerns made it more likely that they ordered specialized pathology tests, obtained recuts, and sought a second opinion, none of these practices were associated with past malpractice. Most dermatopathologists reported also having concerns about patient harms that could result from interpretations of melanocytic lesions.

"The majority of dermatopathologists report that concerns about malpractice affect their interpretive behavior, especially for requesting second opinions and requesting additional slides be cut from the tissue block," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »